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Abstract
The aim of this report is to present a
case of a patient with a recurrent nasal cav-
ity amelanotic melanoma (AM), with
emphasis on diagnosis and therapy options
of this clinical entity. A 65-year-old female
patient presented with pain in the right
cheek region and nasal obstruction. In 2013,
she was diagnosed with mucosal melanoma
(MM) of the left nasal cavity. After endo-
scopic surgery and radiotherapy, the patient
was followed by the oncology team. Five
years after the initial diagnosis, rhinoscopy
showed a tumorous formation in the right
nasal cavity. The tumor mass was without
black discoloration and was the same color
as the surrounding nasal mucosa.
Microscopic examination after biopsy of
the tumor confirmed amelanotic MM. The
patient underwent an additional endoscopic
surgery. A complete standard diagnostic
workup for MM found metastases in head
and neck lymph nodes, on both sides. MMs
of head and neck are uncommon malignan-
cies. Unique biology of MM cells causes a
high rate of recurrences. This report pres-
ents an example of recurrent AM of the
nasal cavity, in treatment with checkpoint
inhibitor (pembrolizumab), which could




melanocytes is the first step in the develop-
ment of malignant melanoma. Melanocytes,
pigment – producing cells migrate from the
neural crest to the skin, mucous mem-
branes, upper esophagus, eyes, and
meninges. Cells in each of these locations
have the potential for genetic and epigenetic
alterations. Malignant mucosal melanomas
(MM) are rare cancers. MM represents only
1.3% of all melanomas. In 2013, 830 newly
diagnosed cases were estimated to occur in
Europe, but its incidence appears to be
increasing. MM of the head and neck region
involve the nose and paranasal sinuses, oral
cavity, pharynx, and larynx. Nasal MMs are
clinically rare, only 4% of all nasal
tumors.1,2 With high recurrence and metas-
tasis rates, nasal MM has a poor prognosis.3
Amelanotic melanomas (AMs) thought to
be biologically more aggressive than other
histopathological variants of MM. Beside
the difficult diagnosis, another challenge
with AM are controversies in the optimal
therapy protocol for this rare tumors.
We present a case with interesting clin-
ical and histopathological features of pri-
mary malignant MM and then recurrent AM
of nasal cavities in a female patient.
Case Report
A 65-year-old female patient consulted
at the Clinic for Otorhinolaryngology of
Clinical Hospital Centre Rijeka, in
September 2018 with nasal obstruction,
right facial pain and sporadic episodes of
epistaxis. From medical history, the patient
had tonsillectomy and nasal polyps surgery
in her childhood. Still, in 2013 she was
diagnosed with MM in left nasal cavity.
Back then, the endoscopic examination
showed a polyploid mass, dark brown to
black, that obstructed the entire left nasal
cavity. A biopsy of the lesion was per-
formed and the microscopic examination
showed metaplastic epithelium, stroma with
numerous enlarged glands and neovascular-
ization. The pathologist described clusters
of atypical melanocytes with a brown pig-
ment in cytoplasm. Immunohistochemistry
showed strong positivity for HMB45, S-100
and microphthalmia-associated transcrip-
tion factor (MITF) (Figure 1). Final diagno-
sis was MM. An multi-slice computed
tomography (MSCT) of the paranasal sinus-
es revealed a tumor mass involving left
inferior and middle nasal turbinates and left
ethmoid cells, and swollen mucosa of
frontal, maxillary and sphenoid sinus
(Figure 2). The structures of the right nasal
cavity were completely tumor-free.
Endoscopic medial maxillactomy was per-
formed and surgeon partially removed the
nasal septum and upper lateral cartilage dur-
ing the procedure. Multiple biopsy speci-
mens from frontal, sphenoid and maxillary
sinus showed no MM. Clinically, there was
no lymphadenopathy and suspected distant
metastasis which was confirmed by neck
ultrasound and positron emission tomogra-
phy-computed tomography (PET/CT). In
2013, patient was staged as T3N0M0. She
received postoperative radiotherapy, with a
total dose of 5400 cGy, in 27 fractions of
conformal radiotherapy. She has been in
regular follow up and in one of them in
2018, similar symptoms appeared, this time
in the right nasal cavity. Anterior
rhinoscopy showed tumor mass in right
middle nasal meatus. The mass was reddish
pink in color without black or brown discol-
oration. MSCT scan of head, orbits, and
sinuses revealed a invasive mass (46×20
mm) involving right inferior and middle
nasal turbinates, and maxillary sinus medial
wall without intracranial and intraorbital
extension (Figure 2). A second endoscopic
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medial maxillectomy was performed. The
histopathology report showed atypical
epithelioid cells and multinucleated giant
cells with eosinophilic cytoplasm. Some
cells were bizarre looking with mitotic
activity and there was no pigment in the
cytoplasm. Tumor cells revealed to be
medium positive for HMB45 and S-100,
and sporadically positive for MITF. This
pathohistology results indicated that the
lesion was AM (Figure 1). The finding of
PET/CT suggested an increased accumula-
tion in the lymph node on the right side
neck in region II (18×9 mm) and left parotid
lymph node (7.6×3.8 mm). Fine needle
aspiration cytology for lymph nodes con-
firmed melanoma metastases. After com-
plete diagnostics workup, tumor was staged
as T4N1M1. Real-time polimerase chain
reaction was performed for mutation detec-
tion of BRAF gene on exon 11 and exon 15,
which did not determine the mutation. The
patient was presented to the multidiscipli-
nary oncology team to determine treatment
plan. Taking into account previous treat-
ment programmed cell death-1 protein (PD-
1) inhibitor, pembrolizumab was intro-
duced. The patient received third dose, and
treatment is ongoing. On last checkup there
is no symptoms and clinical signs of new
metastases or recurrence of local disease. 
Discussion
We present a patient that developed a
rare MM of the left nasal cavity and, in
addition, few years later a recurrent amelan-
otic variant on the opposite, right side. The
present case raises the question whether this
is a recurrence or a new-found MM. MM
arise primarily in the head and neck regions,
commonly in nasal cavity involving the
turbinates and nasal wall. Among nasal MM
cases rare were describe as AMs.1 Thus,
some authors presented a case of AM in
female patient with a mass in left nasal, and
other a case of sinonasal cavity AM with
intraoral extension.4,5 Local recurrences in
MM occur in about 50% of cases.2,6 This
could be the main reason for poor prognosis
and survival. As a result, five-year survival
in Europe between 2000 and 2007 was only
19-23%.7,8 Reasons for high recurrence rate
are probably the unique MM biology, sub-
mucosal lymphatic spread, vascular inva-
sion, and deficient surgical resection.3 The
intranasal endoscopic surgery remains con-
troversial due to difficulty of controlling
surgical margins. Most authors report that
endoscopic resections are being performed
commonly and may be accomplished with
less complications while maintaining onco-
logic efficacy.2,3,6 The sentinel lymph node
biopsy, used in cutaneous melanoma, is still
controversial in MM. However, no signifi-
cant difference in five-year survival has
been observed in patients with or without
lymph node reccurence.3 That was also a
reason to avoid the therapeutic neck dissec-
tion in our patient. In one of rare reports
found in the literature, Sharma et al. pre-
sented a case of male patient with oral MM,
following the recurrent amelanotic variant
of the upper lip after 4 years and primary
surgical treatment for oral MM.9 The reason
for recurrence of MM in our patient is diffi-
cult to explain since it occurred in the oppo-
site nasal cavity and additionally, with dif-
ferent histological feature as well probably
varied biological characteristics. Opposite
to cutaneous melanoma, the biology of MM
is poorly understood. No risk factor has
been identified to explain the development
of MM.1 It is well-known that malignant
transformation of melanocytes is associated
with the accumulation of genetic and
molecular alterations in multiple signaling
pathways. The MAPK pathway has been of
interest since the discovery of frequent acti-
vating mutations of the BRAF kinase.
Unlike skin melanoma, BRAF mutations in
MM are uncommon, as it was not found in
our case. BRAF mutation is detected in 3-
5% of head and neck MM.1-3,6 According to
Amit et al. there is no association between
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Figure 1. Microscopic examination (HE, magnification ×400). A) In 2013, atypical melanocytes with a brown pigment in cytoplasm.
B) In 2018, pleomorphic, multinucleated giant cells with no pigment in cytoplasm. Immunohistochemistry staining profiles (magnifi-
cation ×100). C, D) S-100 strong staining in both melanomas, primary and recurrent. E) HMB45 strong staining in primary mucosal
melanoma. F) Moderate HMB45 staining in recurrent melanoma. G) Microphthalmia-associated transcription factor strong staining
in primary mucosal melanoma. H) Weak microphthalmia-associated transcription factor staining in recurrent amelanotic melanoma.
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mutations status and survival outcomes in
sinonasal MM patients.10 One of the tran-
scriptional factors regulated by MAPK
pathway is microphthalmia-associated tran-
scription factor. MITF is essential for
melanocyte differentiation, it can alterna-
tively promote malignant behavior as an
oncogene.2,11 In 2013, we demonstrated the
MITF immunohistochemistry amplification
in the primary MM of the left nasal cavity
however in recurrent AM the MITF expres-
sion was lower. Thus, immunohistochemi-
cal markers, HMB45 and S-100, despite
lower expression compare to primary MM,
were essential in diagnosis of recurrent AM.
MM lacking or with very low levels of
melanin may grow more rapidly than pig-
mented melanomas. It is important to
emphasize the possible chemotherapeutics
and radiotherapy effect on melanogenesis,
basic process for melanoma cells thus
changing the tumor cells biology.11,12 Vierne
et al. reported an histologically different,
mainly amelanotic mandibular metastasis
16 years after adjuvant radiotherapy treat-
ment for primary cutaneous melanoma.13
This fact opens up various dilemmas in
determination of the right MM therapy.
After MM staging, established by the
American Joint Committee on Cancer, com-
plete surgical excision is first-line treat-
ment.1 MM are composed of cells with high
post-irradiation regenerative capacity, but
radiation dose of 54 Gy improves local con-
trol in some studies.1-4 However, the find-
ings are controversial. In case of our patient
the question arises: was the adjuvant radio-
therapy crucial for changing the biology of
MM into an amelanotic, aggressive variant?
In search for right therapy choice, anti-PD-
1 antibodies are implicated as potential
option. Anti-PD-1 immunotherapy signifi-
cantly prolong survival in patients with
cutaneous melanoma and metastatic
melanoma.2,14 The results of this therapy in
patients with MM are lacking. Clinical trials
addressing the activity of these agents in
patients with MM are necessary to clarify
the role of anti-PD-1 immunotherapy.
Conclusions
Single case reports as ours are signifi-
cant to clinical practice, especially in
absence of clinical guidelines for MM treat-
ment. We put emphasis on fact that there are
critical differences between mucosal and
cutaneous melanoma, which must influence
future clinical decision-making. Hopes for
improvement of poor survival in MM
patients are based on progress in endoscop-
ic surgery, immunotherapies and targeted
treatments.
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Figure 2. Transverse computed tomography. A) In 2013, invasive mass involving inferior
and middle nasal meatus of left nasal cavity. B) In 2018, mass involving right inferior and
middle nasal meatus.
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